<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of pheochromocytoma in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of pheochromocytoma in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of pheochromocytoma in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William F Young, Jr, MD, MSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Electron Kebebew, MD, FACS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynnette K Nieman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sally E Carty, MD, FACS</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wenliang Chen, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 12, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pheochromocytoma is a rare neuroendocrine tumor, occurring in less than 0.2 percent of patients with hypertension [<a href="#rid1">1,2</a>]. In approximately 60 percent of patients, the tumor is discovered incidentally during computed tomography (CT) or magnetic resonance imaging (MRI) of the abdomen for unrelated symptoms [<a href="#rid3">3</a>].</p><p>The treatment of pheochromocytoma will be reviewed here  (<a class="graphic graphic_algorithm graphicRef81154" href="/z/d/graphic/81154.html" rel="external">algorithm 1</a>). The clinical manifestations, diagnosis, and genetics of pheochromocytoma and management of metastatic pheochromocytoma are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/130.html" rel="external">"Clinical presentation and diagnosis of pheochromocytoma"</a> and  <a class="medical medical_review" href="/z/d/html/133.html" rel="external">"Pheochromocytoma in genetic disorders"</a> and  <a class="medical medical_review" href="/z/d/html/86953.html" rel="external">"Paraganglioma and pheochromocytoma: Management of malignant (metastatic) disease"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MEDICAL PREPARATION FOR SURGERY</span><span class="headingEndMark"> — </span>Once a pheochromocytoma is diagnosed, all patients should undergo a resection of the pheochromocytoma following appropriate medical preparation. Agents known to provoke a pheochromocytoma paroxysm (eg, beta-adrenergic blocker in absence of alpha-adrenergic blockade, <a class="drug drug_general" data-topicid="8493" href="/z/d/drug information/8493.html" rel="external">glucagon</a>, histamine, <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a>, high-dose corticosteroids) should be avoided. Our approach is largely consistent with the Endocrine Society's 2014 <a class="external" href="/external-redirect?target_url=https%3A%2F%2Facademic.oup.com%2Fjcem%2Farticle%2F99%2F6%2F1915%2F2537399&amp;token=gHThAtb%2BlQbqahwngRdd1Oj1hi%2FROCWRcogLPZ%2F9twG%2BWb59P8tY5oTa1d5NXbZrTQSH1sovqPIu2wmHohmDqw%3D%3D&amp;TOPIC_ID=142" target="_blank">Clinical Practice Guidelines</a> [<a href="#rid4">4</a>].</p><p>Resecting a pheochromocytoma is a high-risk surgical procedure and an experienced surgeon/anesthesiologist team is required. Cardiovascular and hemodynamic variables must be monitored closely. Continuous measurement of intraarterial pressure and heart rhythm is required. In the setting of congestive heart failure or decreased cardiac reserve, monitoring of pulmonary capillary wedge pressure is indicated.</p><p>Preoperative medical therapy is aimed at:</p><p class="bulletIndent1"><span class="glyph">●</span>Controlling hypertension (including preventing a hypertensive crisis during surgery) and tachycardia</p><p class="bulletIndent1"><span class="glyph">●</span>Volume expansion</p><p></p><p>In patients with undiagnosed pheochromocytomas who undergo surgery for other reasons (and who therefore have not undergone preoperative medical therapy), surgical mortality rates are increased due to lethal hypertensive crises, malignant arrhythmias, and multiorgan failure [<a href="#rid5">5</a>]. Some form of preoperative pharmacologic preparation is indicated for all patients with catecholamine-secreting neoplasms. No randomized, controlled trials have compared the different approaches, and there is no universally accepted method of preparation for surgery in patients with pheochromocytoma [<a href="#rid6">6</a>]. Combined alpha and beta-adrenergic blockade, calcium channel blockers, and <a class="drug drug_general" data-topicid="9647" href="/z/d/drug information/9647.html" rel="external">metyrosine</a> have all been used successfully and are described below [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H192460729"><span class="h2">Combined alpha and beta-adrenergic blockade</span><span class="headingEndMark"> — </span>Combined alpha and beta-adrenergic blockade is one approach to control blood pressure and prevent intraoperative hypertensive crises.</p><p class="headingAnchor" id="H3"><span class="h3">Alpha-adrenergic blockade</span><span class="headingEndMark"> — </span>An alpha-adrenergic blocker is given for at least 7 days preoperatively to normalize blood pressure and expand the contracted intravascular space. A longer duration of preoperative alpha-adrenergic blockade is indicated in patients with recent myocardial infarction, catecholamine cardiomyopathy, refractory hypertension, and catecholamine-induced vasculitis.</p><p><a class="drug drug_general" data-topicid="9764" href="/z/d/drug information/9764.html" rel="external">Phenoxybenzamine</a> is the preferred drug for preoperative preparation to control blood pressure and arrhythmia in most centers in the United States. It is an irreversible, long-acting, nonspecific alpha-adrenergic blocking agent.</p><p class="bulletIndent1"><span class="glyph">●</span>The initial dose is 10 mg once or twice daily, and the dose is increased by 10 to 20 mg in divided doses every two to three days as needed to control blood pressure and spells. In general, the patient is ready for surgery in 7 to 14 days after initiation of alpha-adrenergic blockade.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The final dose of <a class="drug drug_general" data-topicid="9764" href="/z/d/drug information/9764.html" rel="external">phenoxybenzamine</a> is typically between 20 and 100 mg daily. The patient should be warned about the orthostasis, nasal stuffiness, and marked fatigue that occur in almost all patients. Men should be counseled about retrograde ejaculation, as well.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>With their more favorable side-effect profiles and lower financial cost, selective alpha-1-adrenergic blocking agents (eg, <a class="drug drug_general" data-topicid="9806" href="/z/d/drug information/9806.html" rel="external">prazosin</a>, <a class="drug drug_general" data-topicid="9975" href="/z/d/drug information/9975.html" rel="external">terazosin</a>, or <a class="drug drug_general" data-topicid="9389" href="/z/d/drug information/9389.html" rel="external">doxazosin</a>) are utilized in many centers or are preferred to <a class="drug drug_general" data-topicid="9764" href="/z/d/drug information/9764.html" rel="external">phenoxybenzamine</a> when long-term pharmacologic treatment is indicated (eg, for metastatic pheochromocytoma).</p><p></p><p class="headingAnchor" id="H192460828"><span class="h4">Blood pressure monitoring</span><span class="headingEndMark"> — </span>Blood pressure should be monitored twice daily in the outpatient setting with the patient in the seated and standing positions. Target blood pressure is low-normal blood pressure for age (eg, less than 120/80 mmHg seated), with systolic blood pressure greater than 90 mmHg (standing); both targets should be modified on the basis of the patient's age and comorbid disease.</p><p class="headingAnchor" id="H192460836"><span class="h4">High sodium diet</span><span class="headingEndMark"> — </span>On the second or third day of alpha-adrenergic blockade, patients are encouraged to start a diet high in sodium content (&gt;5000 mg daily) because of the catecholamine-induced volume contraction and the orthostasis associated with alpha-adrenergic blockade. This degree of volume expansion may be contraindicated in patients with congestive heart failure or renal insufficiency.</p><p class="headingAnchor" id="H5"><span class="h3">Beta-adrenergic blockade</span><span class="headingEndMark"> — </span>After adequate alpha-adrenergic blockade has been achieved, beta-adrenergic blockade is initiated, which typically occurs two to three days preoperatively. The beta-adrenergic blocker should <strong>never</strong> be started first, because blockade of vasodilatory peripheral beta-adrenergic receptors with unopposed alpha-adrenergic receptor stimulation can lead to a further elevation in blood pressure [<a href="#rid4">4</a>].</p><p>The clinician should exercise caution if the patient is asthmatic or has congestive heart failure. Chronic catecholamine excess can produce a cardiomyopathy that may become evident with the initiation of beta-adrenergic blockade, resulting in acute pulmonary edema. Therefore, when the beta-adrenergic blocker is administered, it should be used cautiously and at a low dose.</p><p class="bulletIndent1"><span class="glyph">●</span>As an example, a patient may be given 10 mg of <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> orally every six hours on the first day of beta-adrenergic blockade. Another option is to start with low-dose <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> (eg, 12.5 mg twice daily).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On the second day, the beta-adrenergic blockade (assuming the patient tolerates the drug) is converted to a single, long-acting dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The dose is then increased as necessary to control the tachycardia (goal heart rate is 60 to 80 beats per minute). Typical maximum doses in this setting are 120 mg of <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> or 200 mg of <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a>.</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Calcium channel blockers</span><span class="headingEndMark"> — </span>Although perioperative alpha-adrenergic blockade is widely recommended, a second regimen that has been utilized involves the administration of a calcium channel blocker [<a href="#rid8">8,9</a>]. <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">Nicardipine</a> and <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">amlodipine</a> are the most commonly used calcium channel blockers in this setting; the starting dose of nicardipine is 30 mg twice daily of the sustained-release preparation and the starting dose of amlodipine is 2.5 or 5 mg administered once daily. The calcium channel blocker is given orally to control blood pressure preoperatively and nicardipine may be given as an intravenous infusion intraoperatively. Although there is less collective experience with calcium channel blockers than with alpha and beta-adrenergic blockade, when calcium channel blockers are used as the primary mode of antihypertensive therapy, they may be as effective [<a href="#rid9">9,10</a>].</p><p>Clearly, the exclusive use of calcium channel blockers for the perioperative management of patients with catecholamine-secreting tumors does not prevent all hemodynamic changes; however, its use has been associated with low morbidity and mortality [<a href="#rid9">9</a>].</p><p>The main role for this class of drugs may be either to supplement the combined alpha- and beta-adrenergic blockade protocol when blood pressure control is inadequate or to replace the adrenergic blockade protocol in patients with intolerable side effects.</p><p class="headingAnchor" id="H7"><span class="h2">Metyrosine</span><span class="headingEndMark"> — </span>Another approach involves the administration of <a class="drug drug_general" data-topicid="9647" href="/z/d/drug information/9647.html" rel="external">metyrosine</a> (alpha-methyl-para-tyrosine), which inhibits catecholamine synthesis. In one report, the patients given metyrosine had a smoother perioperative course than those given <a class="drug drug_general" data-topicid="9764" href="/z/d/drug information/9764.html" rel="external">phenoxybenzamine</a> alone [<a href="#rid11">11</a>].</p><p><a class="drug drug_general" data-topicid="9647" href="/z/d/drug information/9647.html" rel="external">Metyrosine</a> should be used with caution and only when other agents have been ineffective or in patients where tumor manipulation or destruction (eg, radiofrequency ablation of metastatic sites) will be marked [<a href="#rid12">12,13</a>]. Although some centers advocate that this agent should be used routinely preoperatively, most reserve it primarily for patients who cannot be treated with the typical combined alpha and beta-adrenergic blockade protocol because of intolerance or cardiopulmonary reasons [<a href="#rid7">7</a>].</p><p>The protocol used at the Mayo Clinic with short-term preprocedure preparation is to start with <a class="drug drug_general" data-topicid="9647" href="/z/d/drug information/9647.html" rel="external">metyrosine</a> 250 mg every six hours on day 1, 500 mg every six hours on day 2, 750 mg every six hours on day 3, and 1000 mg every six hours on the day before the procedure, with the last dose (1000 mg) the morning of the procedure [<a href="#rid7">7,14</a>]. With this short-course metyrosine therapy, the main side effect is hypersomnolence.</p><p>The side effects of <a class="drug drug_general" data-topicid="9647" href="/z/d/drug information/9647.html" rel="external">metyrosine</a> can be disabling and with long-term therapy they include sedation, depression, diarrhea, anxiety, nightmares, crystalluria and urolithiasis, galactorrhea, and extrapyramidal signs. Metyrosine may be added to alpha and beta-adrenergic blockade when the resection will be difficult (eg, malignant paraganglioma) or if destructive therapy is planned (eg, radiofrequency ablation of hepatic metastases or cryoablation of bone metastases) [<a href="#rid7">7,12,13</a>].</p><p>The extrapyramidal effects of phenothiazines or <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a> may be potentiated, and their use concomitantly with <a class="drug drug_general" data-topicid="9647" href="/z/d/drug information/9647.html" rel="external">metyrosine</a> should be avoided. High fluid intake to avoid crystalluria is suggested for any patient taking more than 2 g daily. The metyrosine-phenoxybenzamine regimen has not been compared with the phenoxybenzamine-beta-adrenergic blocker regimen. The cost of metyrosine has increased dramatically recently and may make use of this medication prohibitive.</p><p class="headingAnchor" id="H8"><span class="h1">ADRENALECTOMY</span></p><p class="headingAnchor" id="H3266643125"><span class="h2">Localized adrenal pheochromocytoma</span><span class="headingEndMark"> — </span>A minimally invasive approach to the adrenal gland is the procedure of choice for patients with small, solitary intraadrenal pheochromocytomas that have no malignant radiologic features. Laparoscopic or robotic transabdominal and retroperitoneal approaches have been used successfully, although there is some evidence that the retroperitoneal approach is preferable [<a href="#rid15">15-18</a>]. Key to success is an endocrine surgeon with expertise in robotic or laparoscopic techniques and operating on pheochromocytomas. Inexperience can lead to critical errors in management; for example, intraoperative tumor capsule rupture with seeding of the retroperitoneum and creating an incurable situation [<a href="#rid19">19</a>].</p><p>Minimally invasive adrenalectomy can be safely performed for pheochromocytoma in more than 90 percent of cases. As an example, in an observational study of 102 patients with pheochromocytoma, 97 adrenalectomies were performed laparoscopically, seven were performed with open surgery, and four required conversion from laparoscopic to open surgery [<a href="#rid20">20</a>].</p><p>If the pheochromocytoma is in the adrenal gland, the entire gland should be removed in sporadic cases. (See <a class="local">'Metastatic pheochromocytoma'</a> below.)</p><p class="headingAnchor" id="H1673450675"><span class="h2">Paragangliomas</span><span class="headingEndMark"> — </span>Abdominal paragangliomas can also be approached laparoscopically in selected cases [<a href="#rid21">21</a>]. Conversion to an open operation from laparoscopic surgery for pheochromocytoma or abdominal paragangliomas is indicated if it is technically difficult to access the tumor or if malignant disease is suspected [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/86953.html" rel="external">"Paraganglioma and pheochromocytoma: Management of malignant (metastatic) disease"</a>.)</p><p>Paragangliomas of the neck, chest, and urinary bladder require specialized approaches [<a href="#rid23">23</a>]. For example, neck paragangliomas may be in the carotid sheath or in the carotid body and thus require proximal and distal vascular control for resection. Preoperative embolization may reduce blood loss [<a href="#rid24">24</a>]. Most chest paragangliomas require a median sternotomy and may involve the heart and great vessels with cardiac bypass, although videoscopic removal may be possible in some cases [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/z/d/html/86542.html" rel="external">"Paragangliomas: Treatment of locoregional disease"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Familial pheochromocytoma</span><span class="headingEndMark"> — </span>Up to 40 percent of pheochromocytomas and paragangliomas are associated with hereditary syndromes [<a href="#rid23">23,26</a>]. Patients with familial pheochromocytomas (eg, MEN2, VHL) have a high incidence of bilateral disease. Partial adrenalectomy can be considered for some patients with familial pheochromocytoma (ie, multiple endocrine neoplasia type 2 [MEN2] and von Hippel-Landau [VHL]) [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/z/d/html/133.html" rel="external">"Pheochromocytoma in genetic disorders", section on 'Familial pheochromocytoma'</a>.)</p><p>Cortical-sparing bilateral adrenalectomy (partial adrenalectomy) may be considered for some patients with bilateral pheochromocytomas to prevent permanent glucocorticoid deficiency because some types of familial pheochromocytomas have less metastatic potential [<a href="#rid27">27-34</a>].</p><p>In a multicenter consortium-based registry, 849 adrenalectomies were performed between 1950 and 2018 in 625 patients with bilateral pheochromocytomas [<a href="#rid27">27</a>]. Approximately one-half of the adrenalectomies (324; 52 percent) were planned as cortical sparing and were successful in 248 patients (76.5 percent) [<a href="#rid27">27</a>]. Primary adrenal insufficiency occurred in all patients treated with total adrenalectomy but only in 23.5 percent of patients treated with attempted cortical-sparing adrenalectomy. Two patients developed recurrent pheochromocytoma in the adrenal bed despite total adrenalectomy, whereas 33 patients (13 percent) treated with successful cortical-sparing adrenalectomy developed another pheochromocytoma within the remnant adrenal after a median of eight years, all of which were successfully treated with another surgery.</p><p>The management of patients with MEN2 and VHL differs as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with <strong>MEN2</strong> have bilateral disease in 30 percent of cases and contralateral disease develops in 50 percent of the MEN2 patients with unilateral disease within 10 years [<a href="#rid26">26,35,36</a>]. For these reasons, when bilateral adrenal pheochromocytomas &gt;2 cm in diameter are present, consideration of <strong>complete</strong> bilateral adrenalectomy is recommended for MEN2 patients. If <strong>partial </strong>adrenalectomies are performed for bilateral pheochromocytoma in the setting of MEN2, the patient should be informed about the risk of recurrent disease (3 percent in the remnant gland occurring 6 to 13 years after partial adrenalectomy) and need for annual long-term follow-up [<a href="#rid34">34</a>]. Patients with MEN2 have a high incidence of paroxysmal attacks and a higher prevalence of hypertension and other cardiovascular problems than do patients with VHL [<a href="#rid26">26,34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with some forms of <strong>VHL</strong> have less diffuse medullary disease, and cortical-sparing bilateral adrenalectomy is an option for these patients when bilateral disease is evident on imaging [<a href="#rid30">30</a>]. However, partial adrenalectomy potentially leaves residual adrenal medullary tissue behind, thus increasing the risk of recurrent pheochromocytoma [<a href="#rid37">37</a>]. In one study, as an example, 13 of 14 patients with VHL did not require glucocorticoid therapy during a mean of 11 years of follow-up; however, three patients had recurrent pheochromocytoma [<a href="#rid30">30</a>]. Similarly, in a study of 36 partial adrenalectomies in 26 patients with VHL, three patients became steroid dependent (11 percent), and there were five local recurrences (11 percent) with nine years of follow-up [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some variant forms of VHL (VHL type 2A) have high malignancy rates, and cortical-sparing adrenalectomy should be avoided in patients from these kindreds [<a href="#rid39">39</a>]. Patients with VHL should be referred for genetic counseling and screening for specific mutations associated with these variants. (See  <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">"Clinical features, diagnosis, and management of von Hippel-Lindau disease"</a>.)</p><p></p><p>If a bilateral adrenalectomy is planned preoperatively, the patient should receive glucocorticoid stress coverage while awaiting transfer to the operating room. (See  <a class="medical medical_review" href="/z/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults"</a> and  <a class="medical medical_review" href="/z/d/html/16322.html" rel="external">"Persistent or recurrent Cushing disease: Surgical adrenalectomy", section on 'Hormone replacement'</a>.)</p><p>Glucocorticoid coverage should be initiated in the operating room if unexpected bilateral adrenalectomy is necessary. Complete bilateral adrenalectomy with autotransplantation of adrenocortical tissue has also been attempted but has <strong>not</strong> been found to circumvent the need for lifelong glucocorticoid replacement therapy [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Surgical outcomes</span><span class="headingEndMark"> — </span>Although no randomized trial data are available, observational studies and literature reviews report that intraoperative blood loss is less, perioperative pain, operative time is shorter, length of hospital stay is shorter, and costs are lower with laparoscopic when compared with open adrenalectomy [<a href="#rid41">41-48</a>].</p><p>Complications of surgery for pheochromocytoma are primarily due to severe preoperative hypertension, high secretion tumors, or repeat intervention for recurrence [<a href="#rid49">49</a>]. As an example, in a series of 143 patients who had open surgery, adverse perioperative events or complications occurred in 32 percent of cases [<a href="#rid50">50</a>]. The most common adverse event was sustained hypertension in 36 patients (25 percent). There were no perioperative deaths, myocardial infarctions, or cerebrovascular events. Perioperative factors associated with adverse perioperative events included larger tumor size, prolonged duration of anesthesia, and increased levels of preoperative urinary catecholamines and catecholamine metabolites. Despite premedication of most patients with <a class="drug drug_general" data-topicid="9764" href="/z/d/drug information/9764.html" rel="external">phenoxybenzamine</a> and a beta-adrenergic blocker, varying degrees of intraoperative hemodynamic lability occurred [<a href="#rid50">50</a>]. In a second study, additional factors associated with adverse perioperative events included systolic blood pressure ≥160 mmHg, mean arterial pressure &lt;60 mmHg, and a history of coronary artery disease [<a href="#rid51">51</a>].</p><p>Complication rates are lower with laparoscopic surgery as compared with open surgery. In a report of 40,363 patients who underwent adrenalectomies between 1998 and 2006, the surgical outcomes were improved with laparoscopic adrenalectomy as compared with open surgery with regard to complication rates (4 versus 8 percent), pulmonary compromise (2 versus 4 percent), and length of hospital stay (three versus five days) [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Acute hypertensive crises</span><span class="headingEndMark"> — </span>In spite of preoperative medical preparation, hemodynamic instability may still occur during surgical resection of a pheochromocytoma. Endotracheal intubation and manipulation of the adrenal gland can both induce release of catecholamines and, potentially, a hypertensive crisis.</p><p>Potential risk factors for intraoperative hemodynamic instability were identified in a retrospective study of 73 patients undergoing surgical resection of a pheochromocytoma at a single institution [<a href="#rid53">53</a>]. Higher preoperative plasma norepinephrine concentration, larger tumor size (&gt;4 cm), and more pronounced postural blood pressure fall after alpha-adrenergic blockade (&gt;10 mmHg) correlated with intraoperative hypertensive events.</p><p class="headingAnchor" id="H12"><span class="h3">Management</span><span class="headingEndMark"> — </span>Treatment options for hypertensive crises include intravenous sodium <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a>, <a class="drug drug_general" data-topicid="9767" href="/z/d/drug information/9767.html" rel="external">phentolamine</a>, or <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">nicardipine</a>.</p><p class="bulletIndent1"><span class="glyph">●</span>Sodium <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a> is an ideal vasodilator for intraoperative management of hypertensive episodes because of its rapid onset of action and short duration of effect. It is administered as an intravenous infusion at 0.5 to 5.0 mcg/kg of body weight per minute and adjusted every few minutes for target blood pressure response; to keep the steady-state thiocyanate concentration below 1 mmol/L, the rate of a prolonged infusion should be no more than 3 mcg/kg per minute.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9767" href="/z/d/drug information/9767.html" rel="external">Phentolamine</a> is a short-acting, nonselective alpha-adrenergic blocker available in lyophilized form in 5 mg vials. An initial test dose of 1 mg is administered and, if necessary, followed by repeat 5 mg boluses or continuous infusion. The response to phentolamine is maximal in two to three minutes after a bolus injection and lasts 10 to 15 minutes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">Nicardipine</a> can be started at an infusion rate of 5 mg/hour and titrated for blood pressure control (the infusion rate may be increased by 2.5 mg/hour every 15 minutes up to a maximum of 15 mg/hour).</p><p></p><p class="headingAnchor" id="H13"><span class="h2">Other complications</span></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac arrhythmias should be managed with <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> (50 to 100 mg intravenously) or <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">esmolol</a> (50 to 200 mcg per kg per minute intravenously).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Postoperative hypotension can be avoided by adequate fluid replacement and hypoglycemia (which can occur in 10 to 15 percent of patients due to removal of catecholamine suppression of insulin secretion [<a href="#rid54">54</a>]) by glucose infusion. After tumor removal, catecholamine secretion should fall to normal in approximately one week.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Postoperative hypoglycemia has been reported in patients undergoing adrenalectomy for pheochromocytoma in 4 to 43 percent of patients based upon serum glucose cutoffs of &lt;55 mg/dL (2.78 mmol/L) and &lt;70 mg/dL (3.89 mmol/L), respectively [<a href="#rid55">55,56</a>]. Thus, serum glucose should be monitored for the first 24 to 48 hours postoperatively [<a href="#rid4">4</a>].</p><p></p><p class="headingAnchor" id="H15"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>Surgical removal of a pheochromocytoma does not always lead to long-term cure of pheochromocytoma or hypertension, even in patients with a benign tumor. In one series of 176 patients, pheochromocytoma recurred in 29 (16 percent) and the recurrence was malignant in 15 of the 29 [<a href="#rid57">57</a>]. Recurrence was more likely in patients with familial pheochromocytoma or familial paraganglioma, right adrenal tumors, and extra-adrenal tumors.</p><p>Recurrence rates may be lower than previously estimated [<a href="#rid58">58</a>], particularly in patients with sporadic pheochromocytoma. In a meta-analysis of 13 studies including 430 patients with sporadic pheochromocytoma, the recurrence rate was 3 percent (95% CI 2 to 6 percent) [<a href="#rid59">59</a>]. Mean follow-up time was 77 months, and the mean time to recurrence was approximately 49 months. In spite of these reassuring data for those with sporadic pheochromocytoma, we still suggest long-term monitoring in all patients, even those apparently cured, as recurrences may occur years later. </p><p>Metastatic disease can be discovered as long as 53 years after the initial surgery [<a href="#rid60">60</a>]. Most patients should have annual biochemical screening [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H1947187276"><span class="h1">METASTATIC PHEOCHROMOCYTOMA</span><span class="headingEndMark"> — </span>There are no curative treatments for metastatic pheochromocytoma, unless the sites of disease are surgically resectable. We suggest resection with intent to cure, which may improve symptoms and possibly survival [<a href="#rid61">61,62</a>]. </p><p>Approximately 10 percent of all catecholamine-secreting tumors are malignant. Malignant/metastatic pheochromocytoma are histologically and biochemically the same as benign ones. The diagnosis of malignant pheochromocytoma is based on documentation of metastatic disease. The risk of malignancy is higher for paragangliomas than for pheochromocytomas, especially if the patient has a mutation in succinate dehydrogenase subunit B (<em>SHDB</em>) [<a href="#rid63">63</a>]. Risk is also higher with larger tumors and some forms of variant VHL. (See  <a class="medical medical_review" href="/z/d/html/5231.html" rel="external">"Paragangliomas: Epidemiology, clinical presentation, diagnosis, and histology"</a>.)</p><p>In a report on 272 patients with metastatic pheochromocytoma and paraganglioma, 29 had rapidly progressive disease and 188 had indolent disease [<a href="#rid60">60</a>]. Metastatic disease was diagnosed at a median age of 39 years (range 7 to 83 years), with synchronous metastases in 96 (35 percent) patients. In 176 (65 percent) of patients, metastases developed at a median of 5.5 years (range 0.3 to 53.4 years) from the initial diagnosis. Median overall and disease-specific survivals were 24.6 and 33.7 years, respectively. Shorter survival correlated with male sex, older age at the time of primary tumor, synchronous metastases, larger primary tumor size, elevated dopamine, and not undergoing primary tumor resection. </p><p>An individualized approach to patients with metastatic pheochromocytoma and paraganglioma is warranted. The only reliable clue to the presence of a malignant pheochromocytoma is local invasion or distant metastases, which may occur as long as 53 years after resection. The clinical features and management of malignant pheochromocytomas are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/86953.html" rel="external">"Paraganglioma and pheochromocytoma: Management of malignant (metastatic) disease"</a> and  <a class="medical medical_review" href="/z/d/html/130.html" rel="external">"Clinical presentation and diagnosis of pheochromocytoma", section on 'Tumor characteristics'</a>.)</p><p class="headingAnchor" id="H2584859314"><span class="h2">Systemic therapy</span><span class="headingEndMark"> — </span>The use of systemic therapies, including <a class="drug drug_general" data-topicid="118601" href="/z/d/drug information/118601.html" rel="external">iobenguane I-131 (therapeutic)</a>, to treat patients with malignant pheochromocytomas/paragangliomas is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/86953.html" rel="external">"Paraganglioma and pheochromocytoma: Management of malignant (metastatic) disease"</a>.)</p><p>Radioactive iodine (I<sup>131</sup>) attached to the MIBG molecule produces iobenguane I-131, which functions as a semi-selective agent for malignant pheochromocytoma or paraganglioma. This treatment is only an option for the approximately 60 percent of tumors that take up MIBG as determined by <a class="drug drug_general" data-topicid="9084" href="/z/d/drug information/9084.html" rel="external">iobenguane I-123 (diagnostic)</a> scintigraphy. A lower fraction of dopamine-secreting paragangliomas take up iobenguane I-123.</p><p>Pheochromocytomas and extra-adrenal paragangliomas express somatostatin receptors at a level that is similar to that of other neuroendocrine tumors. Patients whose metastatic tumors express somatostatin receptors may benefit from therapy with radiolabeled somatostatin analogs, such as <sup>177</sup>Lu-DOTATATE. (See  <a class="medical medical_review" href="/z/d/html/86953.html" rel="external">"Paraganglioma and pheochromocytoma: Management of malignant (metastatic) disease", section on 'Peptide receptor radioligand therapy'</a>.)</p><p>Patients with unresectable malignant pheochromocytoma or paraganglioma may benefit from <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> treatment with or without <a class="drug drug_general" data-topicid="98761" href="/z/d/drug information/98761.html" rel="external">olaparib</a> as a second-line therapy to <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> plus <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a> plus <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">dacarbazine</a> [<a href="#rid64">64-66</a>].</p><p class="headingAnchor" id="H280924525"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112785.html" rel="external">"Society guideline links: Adrenal incidentaloma"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/114434.html" rel="external">"Society guideline links: Pheochromocytoma and paraganglioma"</a>.)</p><p class="headingAnchor" id="H31953955"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/17223.html" rel="external">"Patient education: Pheochromocytoma (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span><span class="headingEndMark"> — </span>Pheochromocytoma is a rare neuroendocrine tumor with serious and potentially lethal cardiovascular complications due to the effects of secreted catecholamines. Although the clinical presentation may be quite variable, the classic triad is considered to be episodic headache, sweating, and tachycardia in association with hypertension.</p><p class="headingAnchor" id="H2273516197"><span class="h2">Surgery</span></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with biochemical documentation of pheochromocytoma, we recommend surgical resection of the pheochromocytoma following optimal medical preparation (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Medical preparation for surgery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Because of the reduction in postoperative morbidity, hospital stay, and expense compared with open laparotomy, we suggest laparoscopic adrenalectomy by an experienced endocrine surgeon for adrenal pheochromocytomas (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Adrenalectomy'</a> above.)</p><p></p><p class="headingAnchor" id="H17"><span class="h2">Preoperative preparation</span></p><p class="bulletIndent1"><span class="glyph">●</span>All patients with pheochromocytoma need to undergo preoperative alpha-adrenergic blockade; we suggest <a class="drug drug_general" data-topicid="9764" href="/z/d/drug information/9764.html" rel="external">phenoxybenzamine</a> as the first-line drug (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Alternative drug options and details for drug administration are outlined above. (See <a class="local">'Alpha-adrenergic blockade'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After adequate alpha-adrenergic blockade has been achieved, beta-adrenergic blockade is begun. For beta-adrenergic blockade, we suggest cautious, low-dose administration. As an example, a patient is usually given either 10 mg of <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> every six hours or <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> 12.5 mg twice daily to start. On the second day of treatment, the beta-adrenergic blockade (assuming the patient tolerates the drug) is converted to a single, long-acting dose. The dose is then increased as necessary to control the tachycardia (goal heart rate is 60 to 80 beats per minute). The typical maximum dose for propranolol is 120 mg/day. The beta-adrenergic blocker should <strong>never</strong> be started first. (See <a class="local">'Beta-adrenergic blockade'</a> above.)</p><p></p><p class="headingAnchor" id="H19"><span class="h2">Familial pheochromocytoma</span></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with multiple endocrine neoplasia type 2 (MEN2) (which is a diffuse medullary disease) with evidence of bilateral disease &gt;2 cm in diameter on imaging, we suggest consideration of complete bilateral adrenalectomy because of the risk of recurrent pheochromocytoma (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Familial pheochromocytoma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For most patients with von Hippel-Lindau (VHL) (which is a less diffuse medullary disease) with evidence of bilateral disease on imaging, we suggest cortical-sparing bilateral adrenalectomy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Because of the risk of recurrent disease in these patients, we recommend long-term biochemical monitoring.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with VHL and a high malignancy rate in the kindred, we suggest not performing cortical-sparing adrenalectomy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with MEN2 or VHL with unilateral pheochromocytoma, we suggest unilateral adrenalectomy or partial adrenalectomy if the tumor is small (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). These patients then need annual biochemical testing indefinitely for evidence of contralateral pheochromocytoma.</p><p></p><p class="headingAnchor" id="H20"><span class="h2">Malignant disease</span></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest resection of malignant pheochromocytoma with intent to cure, which may improve symptoms and possibly survival (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Other treatment options for malignant pheochromocytoma are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/86953.html" rel="external">"Paraganglioma and pheochromocytoma: Management of malignant (metastatic) disease"</a>.)</p><p></p><p class="headingAnchor" id="H3728943072"><span class="h1">DISCLOSURE</span><span class="headingEndMark"> — </span>The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.</p><p class="headingAnchor" id="H2775663048"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate would like to acknowledge Norman M Kaplan, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Young WF Jr. Adrenal causes of hypertension: pheochromocytoma and primary aldosteronism. Rev Endocr Metab Disord 2007; 8:309.</a></li><li><a class="nounderline abstract_t">Pacak K, Linehan WM, Eisenhofer G, et al. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001; 134:315.</a></li><li><a class="nounderline abstract_t">Gruber LM, Hartman RP, Thompson GB, et al. Pheochromocytoma Characteristics and Behavior Differ Depending on Method of Discovery. J Clin Endocrinol Metab 2019; 104:1386.</a></li><li><a class="nounderline abstract_t">Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99:1915.</a></li><li><a class="nounderline abstract_t">Lo CY, Lam KY, Wat MS, Lam KS. Adrenal pheochromocytoma remains a frequently overlooked diagnosis. Am J Surg 2000; 179:212.</a></li><li><a class="nounderline abstract_t">Tauzin-Fin P, Sesay M, Gosse P, Ballanger P. Effects of perioperative alpha1 block on haemodynamic control during laparoscopic surgery for phaeochromocytoma. Br J Anaesth 2004; 92:512.</a></li><li><a class="nounderline abstract_t">Butz JJ, Weingarten TN, Cavalcante AN, et al. Perioperative hemodynamics and outcomes of patients on metyrosine undergoing resection of pheochromocytoma or paraganglioma. Int J Surg 2017; 46:1.</a></li><li><a class="nounderline abstract_t">Ulchaker JC, Goldfarb DA, Bravo EL, Novick AC. Successful outcomes in pheochromocytoma surgery in the modern era. J Urol 1999; 161:764.</a></li><li><a class="nounderline abstract_t">Lebuffe G, Dosseh ED, Tek G, et al. The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragangliomas. Anaesthesia 2005; 60:439.</a></li><li><a class="nounderline abstract_t">Combemale F, Carnaille B, Tavernier B, et al. [Exclusive use of calcium channel blockers and cardioselective beta-blockers in the pre- and per-operative management of pheochromocytomas. 70 cases]. Ann Chir 1998; 52:341.</a></li><li><a class="nounderline abstract_t">Steinsapir J, Carr AA, Prisant LM, Bransome ED Jr. Metyrosine and pheochromocytoma. Arch Intern Med 1997; 157:901.</a></li><li><a class="nounderline abstract_t">McBride JF, Atwell TD, Charboneau WJ, et al. Minimally invasive treatment of metastatic pheochromocytoma and paraganglioma: efficacy and safety of radiofrequency ablation and cryoablation therapy. J Vasc Interv Radiol 2011; 22:1263.</a></li><li><a class="nounderline abstract_t">Deljou A, Kohlenberg JD, Weingarten TN, et al. Hemodynamic instability during percutaneous ablation of extra-adrenal metastases of pheochromocytoma and paragangliomas: a case series. BMC Anesthesiol 2018; 18:158.</a></li><li class="breakAll">Young WF Jr. Endocrine hypertension. In: Williams Textbook of Endocrinology, 12th, Melmed S, Polonsky KS, Larsen PR, Kronenberg HM (Eds), Saunders/Elsevier, Philadelphia 2011. p.545.</li><li><a class="nounderline abstract_t">Nehs MA, Ruan DT. Minimally invasive adrenal surgery: an update. Curr Opin Endocrinol Diabetes Obes 2011; 18:193.</a></li><li><a class="nounderline abstract_t">Nomine-Criqui C, Brunaud L, Germain A, et al. Robotic lateral transabdominal adrenalectomy. J Surg Oncol 2015; 112:305.</a></li><li><a class="nounderline abstract_t">Aliyev S, Karabulut K, Agcaoglu O, et al. Robotic versus laparoscopic adrenalectomy for pheochromocytoma. Ann Surg Oncol 2013; 20:4190.</a></li><li><a class="nounderline abstract_t">Bihain F, Klein M, Nomine-Criqui C, Brunaud L. Robotic adrenalectomy in patients with pheochromocytoma: a systematic review. Gland Surg 2020; 9:844.</a></li><li><a class="nounderline abstract_t">Rafat C, Zinzindohoue F, Hernigou A, et al. Peritoneal implantation of pheochromocytoma following tumor capsule rupture during surgery. J Clin Endocrinol Metab 2014; 99:E2681.</a></li><li><a class="nounderline abstract_t">Shen WT, Grogan R, Vriens M, et al. One hundred two patients with pheochromocytoma treated at a single institution since the introduction of laparoscopic adrenalectomy. Arch Surg 2010; 145:893.</a></li><li><a class="nounderline abstract_t">Walz MK, Alesina PF, Wenger FA, et al. Laparoscopic and retroperitoneoscopic treatment of pheochromocytomas and retroperitoneal paragangliomas: results of 161 tumors in 126 patients. World J Surg 2006; 30:899.</a></li><li><a class="nounderline abstract_t">Shen WT, Sturgeon C, Clark OH, et al. Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas. Surgery 2004; 136:1129.</a></li><li><a class="nounderline abstract_t">Neumann HPH, Young WF Jr, Eng C. Pheochromocytoma and Paraganglioma. N Engl J Med 2019; 381:552.</a></li><li><a class="nounderline abstract_t">Power AH, Bower TC, Kasperbauer J, et al. Impact of preoperative embolization on outcomes of carotid body tumor resections. J Vasc Surg 2012; 56:979.</a></li><li><a class="nounderline abstract_t">Brown ML, Zayas GE, Abel MD, et al. Mediastinal paragangliomas: the mayo clinic experience. Ann Thorac Surg 2008; 86:946.</a></li><li><a class="nounderline abstract_t">Pacak K, Eisenhofer G, Ilias I. Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome. Hormones (Athens) 2009; 8:111.</a></li><li><a class="nounderline abstract_t">Neumann HPH, Tsoy U, Bancos I, et al. Comparison of Pheochromocytoma-Specific Morbidity and Mortality Among Adults With Bilateral Pheochromocytomas Undergoing Total Adrenalectomy vs Cortical-Sparing Adrenalectomy. JAMA Netw Open 2019; 2:e198898.</a></li><li><a class="nounderline abstract_t">Diner EK, Franks ME, Behari A, et al. Partial adrenalectomy: the National Cancer Institute experience. Urology 2005; 66:19.</a></li><li><a class="nounderline abstract_t">Neumann HP, Reincke M, Bender BU, et al. Preserved adrenocortical function after laparoscopic bilateral adrenal sparing surgery for hereditary pheochromocytoma. J Clin Endocrinol Metab 1999; 84:2608.</a></li><li><a class="nounderline abstract_t">Baghai M, Thompson GB, Young WF Jr, et al. Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: a role for laparoscopic and cortical-sparing surgery. Arch Surg 2002; 137:682.</a></li><li><a class="nounderline abstract_t">Lee JE, Curley SA, Gagel RF, et al. Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery 1996; 120:1064.</a></li><li><a class="nounderline abstract_t">Walther MM, Herring J, Choyke PL, Linehan WM. Laparoscopic partial adrenalectomy in patients with hereditary forms of pheochromocytoma. J Urol 2000; 164:14.</a></li><li><a class="nounderline abstract_t">Yip L, Lee JE, Shapiro SE, et al. Surgical management of hereditary pheochromocytoma. J Am Coll Surg 2004; 198:525.</a></li><li><a class="nounderline abstract_t">Castinetti F, Qi XP, Walz MK, et al. Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. Lancet Oncol 2014; 15:648.</a></li><li><a class="nounderline abstract_t">Kaltsas GA, Papadogias D, Grossman AB. The clinical presentation (symptoms and signs) of sporadic and familial chromaffin cell tumours (phaeochromocytomas and paragangliomas). Front Horm Res 2004; 31:61.</a></li><li><a class="nounderline abstract_t">Frank-Raue K, Kratt T, Höppner W, et al. Diagnosis and management of pheochromocytomas in patients with multiple endocrine neoplasia type 2-relevance of specific mutations in the RET proto-oncogene. Eur J Endocrinol 1996; 135:222.</a></li><li><a class="nounderline abstract_t">Brauckhoff M, Gimm O, Brauckhoff K, Dralle H. Repeat adrenocortical-sparing adrenalectomy for recurrent hereditary pheochromocytoma. Surg Today 2004; 34:251.</a></li><li><a class="nounderline abstract_t">Benhammou JN, Boris RS, Pacak K, et al. Functional and oncologic outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel-Lindau syndrome after at least 5 years of followup. J Urol 2010; 184:1855.</a></li><li><a class="nounderline abstract_t">Nielsen SM, Rubinstein WS, Thull DL, et al. Genotype-phenotype correlations of pheochromocytoma in two large von Hippel-Lindau (VHL) type 2A kindreds with different missense mutations. Am J Med Genet A 2011; 155A:168.</a></li><li><a class="nounderline abstract_t">Okamoto T, Obara T, Ito Y, et al. Bilateral adrenalectomy with autotransplantation of adrenocortical tissue or unilateral adrenalectomy: treatment options for pheochromocytomas in multiple endocrine neoplasia type 2A. Endocr J 1996; 43:169.</a></li><li><a class="nounderline abstract_t">Col V, de Cannière L, Collard E, et al. Laparoscopic adrenalectomy for phaeochromocytoma: endocrinological and surgical aspects of a new therapeutic approach. Clin Endocrinol (Oxf) 1999; 50:121.</a></li><li><a class="nounderline abstract_t">Gill IS, Soble JJ, Sung GT, et al. Needlescopic adrenalectomy--the initial series: comparison with conventional laparoscopic adrenalectomy. Urology 1998; 52:180.</a></li><li><a class="nounderline abstract_t">Saunders BD, Doherty GM. Laparoscopic adrenalectomy for malignant disease. Lancet Oncol 2004; 5:718.</a></li><li><a class="nounderline abstract_t">Assalia A, Gagner M. Laparoscopic adrenalectomy. Br J Surg 2004; 91:1259.</a></li><li><a class="nounderline abstract_t">Cheah WK, Clark OH, Horn JK, et al. Laparoscopic adrenalectomy for pheochromocytoma. World J Surg 2002; 26:1048.</a></li><li><a class="nounderline abstract_t">Sprung J, O'Hara JF Jr, Gill IS, et al. Anesthetic aspects of laparoscopic and open adrenalectomy for pheochromocytoma. Urology 2000; 55:339.</a></li><li><a class="nounderline abstract_t">Ichikawa T, Mikami K, Suzuki H, et al. Laparoscopic adrenalectomy for pheochromocytoma. Biomed Pharmacother 2002; 56 Suppl 1:149s.</a></li><li><a class="nounderline abstract_t">Matsuda T, Murota T, Oguchi N, et al. Laparoscopic adrenalectomy for pheochromocytoma: a literature review. Biomed Pharmacother 2002; 56 Suppl 1:132s.</a></li><li><a class="nounderline abstract_t">Plouin PF, Duclos JM, Soppelsa F, et al. Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. J Clin Endocrinol Metab 2001; 86:1480.</a></li><li><a class="nounderline abstract_t">Kinney MA, Warner ME, vanHeerden JA, et al. Perianesthetic risks and outcomes of pheochromocytoma and paraganglioma resection. Anesth Analg 2000; 91:1118.</a></li><li><a class="nounderline abstract_t">Brunaud L, Nguyen-Thi PL, Mirallie E, et al. Predictive factors for postoperative morbidity after laparoscopic adrenalectomy for pheochromocytoma: a multicenter retrospective analysis in 225 patients. Surg Endosc 2016; 30:1051.</a></li><li><a class="nounderline abstract_t">Murphy MM, Witkowski ER, Ng SC, et al. Trends in adrenalectomy: a recent national review. Surg Endosc 2010; 24:2518.</a></li><li><a class="nounderline abstract_t">Bruynzeel H, Feelders RA, Groenland TH, et al. Risk Factors for Hemodynamic Instability during Surgery for Pheochromocytoma. J Clin Endocrinol Metab 2010; 95:678.</a></li><li><a class="nounderline abstract_t">Akiba M, Kodama T, Ito Y, et al. Hypoglycemia induced by excessive rebound secretion of insulin after removal of pheochromocytoma. World J Surg 1990; 14:317.</a></li><li><a class="nounderline abstract_t">Chen Y, Hodin RA, Pandolfi C, et al. Hypoglycemia after resection of pheochromocytoma. Surgery 2014; 156:1404.</a></li><li><a class="nounderline abstract_t">Araki S, Kijima T, Waseda Y, et al. Incidence and predictive factors of hypoglycemia after pheochromocytoma resection. Int J Urol 2019; 26:273.</a></li><li><a class="nounderline abstract_t">Amar L, Servais A, Gimenez-Roqueplo AP, et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 2005; 90:2110.</a></li><li><a class="nounderline abstract_t">Amar L, Lussey-Lepoutre C, Lenders JW, et al. MANAGEMENT OF ENDOCRINE DISEASE: Recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and meta-analysis. Eur J Endocrinol 2016; 175:R135.</a></li><li><a class="nounderline abstract_t">Holscher I, van den Berg TJ, Dreijerink KMA, et al. Recurrence Rate of Sporadic Pheochromocytomas After Curative Adrenalectomy: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab 2021; 106:588.</a></li><li><a class="nounderline abstract_t">Hamidi O, Young WF Jr, Iñiguez-Ariza NM, et al. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years. J Clin Endocrinol Metab 2017; 102:3296.</a></li><li><a class="nounderline abstract_t">Ellis RJ, Patel D, Prodanov T, et al. Response after surgical resection of metastatic pheochromocytoma and paraganglioma: can postoperative biochemical remission be predicted? J Am Coll Surg 2013; 217:489.</a></li><li><a class="nounderline abstract_t">Strajina V, Dy BM, Farley DR, et al. Surgical Treatment of Malignant Pheochromocytoma and Paraganglioma: Retrospective Case Series. Ann Surg Oncol 2017; 24:1546.</a></li><li><a class="nounderline abstract_t">Assadipour Y, Sadowski SM, Alimchandani M, et al. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma. Surgery 2017; 161:230.</a></li><li><a class="nounderline abstract_t">Tong A, Li M, Cui Y, et al. Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature. Front Endocrinol (Lausanne) 2020; 11:61.</a></li><li><a class="nounderline abstract_t">Hadoux J, Favier J, Scoazec JY, et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer 2014; 135:2711.</a></li><li><a class="nounderline abstract_t">Granberg D, Juhlin CC, Falhammar H. Metastatic Pheochromocytomas and Abdominal Paragangliomas. J Clin Endocrinol Metab 2021; 106:e1937.</a></li></ol></div><div id="topicVersionRevision">Topic 142 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17914676" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Adrenal causes of hypertension: pheochromocytoma and primary aldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11182843" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30462226" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pheochromocytoma Characteristics and Behavior Differ Depending on Method of Discovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24893135" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10827323" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Adrenal pheochromocytoma remains a frequently overlooked diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14766711" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Effects of perioperative alpha1 block on haemodynamic control during laparoscopic surgery for phaeochromocytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28803996" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Perioperative hemodynamics and outcomes of patients on metyrosine undergoing resection of pheochromocytoma or paraganglioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022680" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Successful outcomes in pheochromocytoma surgery in the modern era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15819762" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragangliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9752467" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : [Exclusive use of calcium channel blockers and cardioselective beta-blockers in the pre- and per-operative management of pheochromocytomas. 70 cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9129550" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Metyrosine and pheochromocytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21856504" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Minimally invasive treatment of metastatic pheochromocytoma and paraganglioma: efficacy and safety of radiofrequency ablation and cryoablation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30400849" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hemodynamic instability during percutaneous ablation of extra-adrenal metastases of pheochromocytoma and paragangliomas: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30400849" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hemodynamic instability during percutaneous ablation of extra-adrenal metastases of pheochromocytoma and paragangliomas: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21494137" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Minimally invasive adrenal surgery: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26179549" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Robotic lateral transabdominal adrenalectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23864309" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Robotic versus laparoscopic adrenalectomy for pheochromocytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32775278" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Robotic adrenalectomy in patients with pheochromocytoma: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25188716" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Peritoneal implantation of pheochromocytoma following tumor capsule rupture during surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20855761" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : One hundred two patients with pheochromocytoma treated at a single institution since the introduction of laparoscopic adrenalectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16617419" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Laparoscopic and retroperitoneoscopic treatment of pheochromocytomas and retroperitoneal paragangliomas: results of 161 tumors in 126 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15657566" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31390501" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pheochromocytoma and Paraganglioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22727841" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Impact of preoperative embolization on outcomes of carotid body tumor resections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18721588" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Mediastinal paragangliomas: the mayo clinic experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19570738" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31397861" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Comparison of Pheochromocytoma-Specific Morbidity and Mortality Among Adults With Bilateral Pheochromocytomas Undergoing Total Adrenalectomy vs Cortical-Sparing Adrenalectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15961144" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Partial adrenalectomy: the National Cancer Institute experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10443647" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Preserved adrenocortical function after laparoscopic bilateral adrenal sparing surgery for hereditary pheochromocytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12049539" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: a role for laparoscopic and cortical-sparing surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8957496" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10840414" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Laparoscopic partial adrenalectomy in patients with hereditary forms of pheochromocytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15051000" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Surgical management of hereditary pheochromocytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24745698" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14674305" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The clinical presentation (symptoms and signs) of sporadic and familial chromaffin cell tumours (phaeochromocytomas and paragangliomas).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8810737" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Diagnosis and management of pheochromocytomas in patients with multiple endocrine neoplasia type 2-relevance of specific mutations in the RET proto-oncogene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999539" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Repeat adrenocortical-sparing adrenalectomy for recurrent hereditary pheochromocytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20846682" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Functional and oncologic outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel-Lindau syndrome after at least 5 years of followup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21204227" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Genotype-phenotype correlations of pheochromocytoma in two large von Hippel-Lindau (VHL) type 2A kindreds with different missense mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8793332" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Bilateral adrenalectomy with autotransplantation of adrenocortical tissue or unilateral adrenalectomy: treatment options for pheochromocytomas in multiple endocrine neoplasia type 2A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10341865" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Laparoscopic adrenalectomy for phaeochromocytoma: endocrinological and surgical aspects of a new therapeutic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9697779" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Needlescopic adrenalectomy--the initial series: comparison with conventional laparoscopic adrenalectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15581542" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Laparoscopic adrenalectomy for malignant disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15376201" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Laparoscopic adrenalectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12045856" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Laparoscopic adrenalectomy for pheochromocytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10699606" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Anesthetic aspects of laparoscopic and open adrenalectomy for pheochromocytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12487272" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Laparoscopic adrenalectomy for pheochromocytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12487269" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Laparoscopic adrenalectomy for pheochromocytoma: a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11297571" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11049893" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Perianesthetic risks and outcomes of pheochromocytoma and paraganglioma resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26092019" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Predictive factors for postoperative morbidity after laparoscopic adrenalectomy for pheochromocytoma: a multicenter retrospective analysis in 225 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20336320" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Trends in adrenalectomy: a recent national review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19965926" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Risk Factors for Hemodynamic Instability during Surgery for Pheochromocytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2195784" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Hypoglycemia induced by excessive rebound secretion of insulin after removal of pheochromocytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25456920" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Hypoglycemia after resection of pheochromocytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30467902" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Incidence and predictive factors of hypoglycemia after pheochromocytoma resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15644401" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27080352" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : MANAGEMENT OF ENDOCRINE DISEASE: Recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33125073" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Recurrence Rate of Sporadic Pheochromocytomas After Curative Adrenalectomy: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28605453" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23891076" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Response after surgical resection of metastatic pheochromocytoma and paraganglioma: can postoperative biochemical remission be predicted?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28058556" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Surgical Treatment of Malignant Pheochromocytoma and Paraganglioma: Retrospective Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27839933" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32132978" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24752622" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33462603" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Metastatic Pheochromocytomas and Abdominal Paragangliomas.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
